# Aer Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aer-therapeutics

- Industry: Biotechnology
- Headquarters: Raleigh, US
- Website: www.aertherapeutics.com
- Total disclosed funding: $16M
- Latest round: Series A (Dec 9, 2022)
- Investors on record: 3

## About

Based in Raleigh, US, and founded in 2014, Aer Therapeutics, a spin-out of Dr. John Fahy’s airway biology lab at the University of California San Francisco (UCSF) in collaboration with Dr. Stefan Oscarson’s glycochemistry lab at University College Dublin and Dr. Anne Marie Healy’s pharmaceutics lab at Trinity College Dublin, operates as a clinical-stage biopharmaceutical company that develops novel therapeutics to treat respiratory diseases. In April 2023, Aer Therapeutics raised USD 36 million in Series A funding from new investors Canaan Partners, Hatteras Venture Partners, and OrbiMed Advisors. As of April 2023, the firm is being led by its CEO, Jim Shaffer. 

The company develops novel inhaled treatments for muco-obstructive lung diseases like asthma, cystic fibrosis, primary ciliary dyskinesia, and non-cystic fibrosis bronchiectasis. AER-01, a thiol-modified carbohydrate, is a product of the company that cleaves mucin disulfide bridges to liquefy mucus plugs, disulfide bridges cross-link mucin polymers, increasing mucus gel elasticity and promote mucus plug formation.

The company intends to use the April 2023 funding to advance the development of AER-01 and plans to initiate a first-in-human Phase 1 clinical trial of AER-01 in mid-2023.

## Funding rounds

- Series A, Dec 9, 2022, $16M — OrbiMed Advisors, Canaan Partners, Hatteras Venture Partners

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series A